180 related articles for article (PubMed ID: 21317931)
21. Doxorubicin induces prolonged DNA damage signal in cells overexpressing DEK isoform-2.
Özçelik E; Kalaycı A; Çelik B; Avcı A; Akyol H; Kılıç İB; Güzel T; Çetin M; Öztürk MT; Çalışkaner ZO; Tombaz M; Yoleri D; Konu Ö; Kandilci A
PLoS One; 2022; 17(10):e0275476. PubMed ID: 36190960
[TBL] [Abstract][Full Text] [Related]
22. First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
Savari O; Chang JC; Bishop JA; Sakthivel MK; Askin FB; Rekhtman N
J Thorac Oncol; 2022 Aug; 17(8):1050-1053. PubMed ID: 35773081
[TBL] [Abstract][Full Text] [Related]
23. Intracellular and extracellular moesins differentially regulate Src activity and β-catenin translocation to the nucleus in breast cancer cells.
Ahandoust S; Li K; Sun X; Li BY; Yokota H; Na S
Biochem Biophys Res Commun; 2023 Jan; 639():62-69. PubMed ID: 36470073
[TBL] [Abstract][Full Text] [Related]
24. DEK::AFF2 Fusion Carcinomas of Head and Neck.
Ruangritchankul K; Sandison A
Adv Anat Pathol; 2023 Mar; 30(2):86-94. PubMed ID: 36221219
[TBL] [Abstract][Full Text] [Related]
25. Potential of
Habiburrahman M; Wardoyo MP; Sutopo S; Rahadiani N
Mol Clin Oncol; 2022 Jul; 17(1):117. PubMed ID: 35747597
[TBL] [Abstract][Full Text] [Related]
26. IMMUNOEXPRESSION OF DEK AND PHOSPHO-P38 PROTEINS IN RECTAL CANCER BEFORE CHEMORADIATION THERAPY.
Tadokoro RB; Cardili L; Artigiani Neto R; Paiotti APR; Oshima CTF; Forones NM
Arq Gastroenterol; 2022; 59(3):414-420. PubMed ID: 36102441
[TBL] [Abstract][Full Text] [Related]
27. Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy.
Ladányi A; Rásó E; Barbai T; Vízkeleti L; Puskás LG; Kovács SA; Győrffy B; Tímár J
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269844
[TBL] [Abstract][Full Text] [Related]
28. [Primary DEK::AFF2 fusion positive nonkeratinizing squamous cell carcinoma of the middle ear: report of a case].
Yu ST; Ye XZ; Xu BQ; Ouyang XJ; Zhang JQ; Qu LJ
Zhonghua Bing Li Xue Za Zhi; 2023 Oct; 52(10):1058-1060. PubMed ID: 37805405
[TBL] [Abstract][Full Text] [Related]
29. Stimulus-responsive and dual-target DNA nanodrugs for rheumatoid arthritis treatment.
Zhang Y; Wang J; Luo R; Guo F; Wang X; Chu X; Zhao Y; Sun P
Int J Pharm; 2023 Feb; 632():122543. PubMed ID: 36572263
[TBL] [Abstract][Full Text] [Related]
30. Super-resolution microscopy reveals the nanoscale cluster architecture of the DEK protein cancer biomarker.
Pierzynska-Mach A; Diaspro A; Cella Zanacchi F
iScience; 2023 Nov; 26(11):108277. PubMed ID: 38026229
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.
Raghuram GV; Pal K; Sriram G; Khan A; Joshi R; Jadhav V; Shinde S; Shaikh A; Rane B; Kangne H; Mittra I
PLoS One; 2024; 19(2):e0298042. PubMed ID: 38346047
[TBL] [Abstract][Full Text] [Related]
32. Short-term exposure to ethanol induces transcriptional changes in nontumorigenic breast cells.
Miller GM; Brant TS; Goodrich JA; Kugel JF
FEBS Open Bio; 2023 Oct; 13(10):1941-1952. PubMed ID: 37572351
[TBL] [Abstract][Full Text] [Related]
33. Correction to: Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.
Wang N; Wang Q; Tang H; Zhang F; Zheng Y; Wang S; Zhang J; Wang Z; Xie X
J Exp Clin Cancer Res; 2022 Mar; 41(1):118. PubMed ID: 35361238
[No Abstract] [Full Text] [Related]
34. Correction to "Novel DEK-Targeting Aptamer Delivered by a Hydrogel Microneedle Attenuates Collagen-Induced Arthritis".
Cao J; Su J; An M; Yang Y; Zhang Y; Zuo J; Zhang N; Zhao Y
Mol Pharm; 2021 Nov; 18(11):4231. PubMed ID: 34582206
[No Abstract] [Full Text] [Related]
35. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
36. Stacking the DEK: from chromatin topology to cancer stem cells.
Privette Vinnedge LM; Kappes F; Nassar N; Wells SI
Cell Cycle; 2013 Jan; 12(1):51-66. PubMed ID: 23255114
[TBL] [Abstract][Full Text] [Related]
37. The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C; Gullberg U
Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
[TBL] [Abstract][Full Text] [Related]
38. Concise review: role of DEK in stem/progenitor cell biology.
Broxmeyer HE; Mor-Vaknin N; Kappes F; Legendre M; Saha AK; Ou X; O'Leary H; Capitano M; Cooper S; Markovitz DM
Stem Cells; 2013 Aug; 31(8):1447-53. PubMed ID: 23733396
[TBL] [Abstract][Full Text] [Related]
39. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
[TBL] [Abstract][Full Text] [Related]
40. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
